We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The pharmaceutical industry will see more mergers and acquisitions in 2021 than in the pandemic-depressed year just ended, top financial firms are saying. Read More
Late Monday, the FDA’s two top officials hinted that the agency is unlikely to adopt the Trump administration’s idea of giving two half doses of Moderna’s COVID-19 vaccine to patients aged 18 to 55 in order to double the number of vaccinations being administered, as suggested by Operation Warp Speed’s chief adviser Moncef Slaoui. Read More
The pricing of COVID-19 vaccines is expected to draw closer scrutiny in the new year — and even closer attention once the vaccines are no longer being issued for free by governments. Read More
With COVID-19 vaccines from Pfizer/BioNTech and Moderna receiving Emergency Use Authorization and others from AstraZeneca (AZ) and Johnson & Johnson (J&J) edging closer to regulatory approval, vaccine developers are now facing a new challenge: What to call their vaccines to make them more attractive — or at least less scary — for the general public? Read More
Pfizer is expanding further into oncology thanks to a deal with Myovant Sciences, under which the two companies will cooperate on developing and commercializing Myovant’s newly approved prostate cancer drug Orgovyx (relugolix). Myovant will receive up to $4.2 billion, including an upfront payment of $650 million. Read More
The U.S. and Pfizer have agreed to another vaccine supply deal that will net the government an additional 100 million doses of Pfizer/BioNTech’s coronavirus vaccine in summer 2021. Read More
French drugmaker Servier is expanding its reach into cancer drugs by acquiring Agios Pharmaceutical’s oncology business in a deal valued at up to $2 billion. Read More
Novartis has agreed to buy Cambridge, Mass.-based Cadent Therapeutics for a possible $770 million, expanding its pipeline of treatments for cognitive and mood disorders. Read More
The planned acquisition continues the growing trend of gene and cell therapy consolidations as large drugmakers expand their reach into the field. Read More